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ABSTRACT 
 
Introduction: 
Cervical squamous cell carcinoma is most commonly caused by persistent infection by high 
risk human papillomavirus (hrHPV) genotypes.  The exact type of hrHPV varies 
geographically and is the basis for HPV–based vaccination for cervical squamous cell 
carcinoma prevention.  Little is known regarding local hrHPV genotypes within the Western 
Cape population of South Africa. 
 
Aims and objectives: 
This was a pilot study aiming to extract of high quality genomic DNA from archival FFPE 
cervical squamous cell carcinoma cases and identify hrHPV genotypes by multiplex real time 
PCR (RT-PCR). 
 
Materials and methods: 
A retrospective search identified a total of 57 cases of cervical squamous cell carcinoma for 
the period 2004-2014.  This was reduced to a final number of 23 that exhibited sufficient 
tumour burden for DNA extraction.  The most common age group was 40-49 years.  HIV status 
was as follows: two HIV-positive, 14 HIV-negative and 7 HIV unknown.  DNA was extracted 
from archival FFPE cervical squamous cell carcinoma samples using QIAGEN QIAamp® 
DNA FFPE Tissue kit.  Housekeeping genes were detected by endpoint PCR using standard 
primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sequences to determine the 
quality and integrity of extracted DNA for downstream PCR amplification experiments.  
HrHPV DNA amplification was optimised using a touchdown PCR technique with L1 
consensus gene GP5+/GP6+ primers.  HrHPV genotypes were detected using a four colour 
multiplex hrHPV genotyping kit.  Samples showing positive results in overlapping probe filter 
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detection spectra were subjected to DNA Sanger sequencing for final confirmation of specific 
hrHPV genotype. 
 
Results: 
Standard xylene DNA extraction methods using QIAamp® system yielded adequate amounts 
of DNA with average final concentration of 463.2 ng/l and A260/A280 ratio of 1.86.  
Housekeeping genes were successfully detected in all samples, confirming that no significant 
DNA degradation of target sequences occurred within the archival time range of 2004-2014.  
HPV L1 detection via GP5+/GP6+ primers with endpoint PCR was not achieved via standard 
cycling conditions and required the use of a touchdown technique with gradually decreasing 
annealing temperatures.  This method successfully identified HPV L1 sequences in 22 out of 
23 cases. 
 
Multiplex RT-PCR with four colour hydrolysis probes identified hrHPV genotypes in 22 of 23 
cases with relative frequencies of HPV genotypes: 16>>18=39=45>33.  Most cases showed 
infection with a single hrHPV genotype (HPV 16 and one case with HPV 33) with four cases 
demonstrating two genotypes (two with HPV 16&18, one with 16&33 and one with 39&45) 
and one case with three genotypes (HPV 16, 39, 45).  Interestingly, none of the HIV-positive 
cases showed multiple hrHPV genotype infection.  Four hrHPV cases with overlapping spectra 
for HPV 18/31 and 45/59 were subjected to Sanger sequencing for confirmation of genotype.  
Three of four cases showed 100% match for genotypes 18 and 45 with the final case 
demonstrating only co-infective HPV 16. 
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Conclusion: 
Commercial DNA extraction kits yield adequate amounts of intact, amplifiable DNA in 
archival FFPE cervical carcinoma specimens.  Touchdown PCR is necessary for HPV detection 
in extracted FFPE DNA cases using GP5+/GP6+ L1 primers.  RT-PCR using multicolour 
hydrolysis probes is a rapid, sensitive technique for hrHPV genotype screening of cervical 
squamous cell carcinoma specimens.  A three colour detection system rather than four colour 
kit is recommended for future studies in order to avoid extra cost in DNA sequencing cases 
with overlapping spectra.  This pilot study demonstrates hrHPV genotype prevalence similar  
to that in other populations and suggests that vaccination with currently available formulations 
would provide a sufficiently wide coverage of HPV genotypes.  Future studies will include 
application of the FFPE DNA extraction, endpoint PCR and RT-PCR techniques to the 
remainder of the cases in the original cohort. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 HPV and cervical carcinoma 
Human papillomavirus (HPV) is a double stranded deoxyribonucleic acid (DNA) virus that 
belongs to the genus Alphapapillomavirus (Kocjan et al., 2016).  The other four HPV genera 
include beta, gamma, mu and nu.  HPV demonstrates tropism towards epithelial cells, infecting 
genital and oral skin and mucosa (Schiffman et al., 2007).  The HPV family of viruses includes 
over 200 types but only a minority of these are implicated in oncogenic transformation (Choi 
and Park, 2015).  The identification of HPV as the aetiological cause of cervical cancer was 
made in the 1970’s by German virologist Dr Harald zur Hausen, for which he won the 2008 
Nobel Prize in Physiology or Medicine.  Each year approximately 266 000 women worldwide 
die of cervical cancer, 90% of whom live in middle to low income countries.  It is the leading 
cause of cancer deaths in Eastern and Central Africa (World Health Organisation, 2014). 
 
South Africa has both a relatively high incidence and mortality rate for cervical carcinoma, 
similar to other sub-Saharan African countries (Figures 1.1 and 1.2).  In South Africa, cervix 
carcinoma is the second most common female cancer and has the highest age-standardised 
death rate of all the top female cancers from 2000-2012 (World Health Organisation, 2014).  
This is thought to be due to a host of contributing factors including poor screening rate, lack of 
awareness, poor access to health care facilities, late presentation of disease (De Vuyst et al., 
2013, Denny et al., 2014).  The high rate of HIV infection is also thought to contribute to the 
high incidence rate (by accelerating the progression from cervical dysplasia to carcinoma) and 
mortality rate (Denny et al., 2014). 
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Figure 1. 1 Age standardised rates (ASR) of cervical cancer incidence in sub-Saharan 
Africa.  Numbers are per 100,000 women (from De Vuyst et al., 2013). 
 
Figure 1. 2 Age standardised rates (ASR) of cervical cancer mortality in sub-Saharan 
Africa.  Numbers are per 100,000 women (from De Vuyst et al., 2013). 
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Cervical carcinoma encompasses squamous cell carcinoma and adenocarcinoma with 
squamous cell carcinoma accounting for at least three quarters of all carcinomas (Vinh-Hung 
et al., 2007).  HrHPV infection is associated with the majority of cervical squamous cell 
carcinomas (reaching almost 100%) and adenocarcinomas (62-100%) (Pirog, 2017) however 
a small portion of either carcinoma arises by non-HPV oncogenic pathways. 
Non-HPV associated adenocarcinomas of the cervix include gastric, endometrial, 
villoglandular, serous and mesonephric adenocarcinoma (Rodriguez-Carunchio et al., 2015).  
Non-HPV related squamous cell carcinoma of the cervix is associated with a poorer prognosis 
compared to conventional hrHPV-related cervical squamous cell carcinoma.  This poorer 
prognosis is also noted in non-HPV related squamous cell carcinomas of the head and neck 
region arising from alcohol and tobacco use (Mirghani and Blanchard, 2018). 
Surveillance, Epidemiology and End Results (SEER) data from the United States of America 
of 30 989 samples for the period 1973-2002 show that the numbers of new cases of squamous 
cell carcinoma have steadily declined (as a result of increased Pap screening) while some 
histological subtypes have increased, such as adenocarcinoma, mucinous and adenosquamous 
(Vinh-Hung et al., 2007).  This trend of decreasing squamous cell carcinoma is not reflecting 
in developing countries where screening facilities are limited and HPV vaccination 
unavailable. 
Cervical carcinoma variants are associated with different prognoses.  For example, patients 
with small cell carcinoma of the cervix have worse 10-year overall survival data (31.6%) than 
mucinous (43%) or adenosquamous carcinoma (50.7%) who, in turn, have worse overall 
survival compared to squamous cell carcinoma (52.3%) (Vinh-Hung et al., 2007). 
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The WHO currently recognises superficially invasive squamous cell carcinoma (depth of 
invasion less than 3 mm) and invasive squamous cell carcinoma.  Variants of invasive 
squamous cell carcinoma include keratinsing, non-keratinising, basaloid, warty, papillary, 
verrucous, lymphoepithelial and squamotransitional (Vinh-Hung et al., 2007).  
1.2 The HPV genome, life cycle and classification 
The structure of HPV includes an icosahedral capsid housing viral DNA. The HPV genome is 
circular and divided into three regions with eight overlapping open reading frames (ORF) 
(Riemer et al., 2010).  These include an early region (E), late region (L) and a long control 
region (LCR) (Figure 1.3). 
1. The early region contains genes E1, E2, E4, E5, E6 and E7.  E1 and E2 are involved in 
transcription and replication.  E6 and E7 bind to and degrade tumour suppressor gene 
products p53 and retinoblastoma (Rb) respectively and play critical roles in 
oncogenesis.  E7 also interacts with other protein targets and is involved in allowing 
the host cell to evade apoptosis and immune surveillance (Choi and Park, 2015). The 
roles of E4 and E5 are less well understood. 
2. The late region contains genes L1 and L2.  These encode major and minor capsid proteins, 
respectively.  These genes are expressed prior to viral escape from host cells.  L2 is also 
essential for permitting viral entry into host cells. 
3. Long control region (LCR).  This is a non-coding regulatory region that is positioned 
upstream between genes E6 and L1.  This region contains a core promoter sequence 
which is involved in regulating DNA replication and gene transcription.  The DNA 
sequence shows variation between HPV genotypes (Choi and Park, 2015). 
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HPV genotypes are classified on the basis of differing L1 gene sequences.  Those with >10% 
differences are considered different genotypes whereas those with >1% and <1% are 
considered intratypic and sub-lineage variants, respectively (Choi and Park, 2015).  HPV 
genotypes are subdivided into low risk and high risk.   
1. High risk HPV genotypes (hrHPV) include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 
and 68. These genotypes are implicated in the development of cervical intra-epithelial 
neoplasia (CIN) and cervical cancer (squamous cell carcinoma and adenocarcinoma). 
2. Low risk HPV genotypes (lrHPV) include 6, 11, 34, 40, 42, 43, 44, 53, 54, 70 and 74.  The 
genotypes are implicated in the development of genital warts, which usually require 
local surgical treatment but are not implicated in the development of CIN or cancer 
(Bernard et al., 2010). 
Most sexually active women become infected with HPV during their lifetime but only 
approximately 10% will become persistently infected.  HrHPV 16 and 18 are responsible for 
~70% of cervical cancer (Bateman et al., 2015). 
Recent years have seen the development and U.S. Food and Drug Administration (FDA) 
approval of three different vaccines targeting HPV genotypes implicated in genital warts 
(lrHPV 6 and 11) and cervical cancer (hrHPV 16 and 18) (Schiffman et al., 2007; Denny et al., 
2014).  Vaccination of female children prior to sexual debut is envisaged to greatly reduce the 
burden of cervical cancer.  These include bivalent vaccine Gardasil (Merck, 2006), 
quadrivalent vaccine Cervarix (Glaxo Smith-Kline, 2007) and nonavalent vaccine Gardasil 9 
(Merck, 2014) (Denny et al., 2014).  Vaccines contain E6/E7 oncoprotein epitopes that elicit a 
strong cellular immune response and can clear hrHPV lesions.  Studies have suggested cross-
protection against other less common hrHPV genotypes (Denny et al., 2014; Salazar et al., 
2015). 
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Figure 1. 3 Schematic diagram of the HPV genome and associated genes (Riemer et al., 
2010) 
 
HrHPV genotypes responsible for the development of cervical, penile, anal and head and neck 
cancers are sexually transmitted.  The life cycle is most well understood in the context of 
cervical cancer where the squamocolumnar junction of the transformation zone has been 
identified as the point of HPV infection (Figure 1.4) (Schiffman et al., 2007; Cohen et al., 
2019).  HPV infects the basal, replicating cells of the epithelium.  Initially HPV replication 
occurs in tandem with host cell replication.  E1 and E2 HPV gene products are required for the 
maintenance of viral infection within the host cell and recruit host DNA polymerase to initiate 
viral genome replication.  E6 and E7 allow for bypassing of normal host apoptotic activation 
with viral infection and they promote increased cellular proliferation and viral production.  As 
the cervical epithelial cells mature as they progress towards the surface, activation of the late 
genes L1 and L2 allow for viral protein capsid formation so that intact virions may be 
assembled and shed when the uppermost layer of host cells are shed.  E4 interacts with host 
cytoskeletal proteins and is responsible for the formation of koilocytes within the uppermost 
regions of the epithelium (Schiffman et al., 2007; Choi and Park, 2015).  The actions of E6 and 
E7 oncoproteins may initiate additional genetic injuries to the host cell as a result of p53 and 
Rb destruction and the resultant dysplastic cells undergo a switch from “productive” infection, 
where HPV DNA is incorporated into capsids to produce infectious virions, to “non-
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productive” infection where late gene expression is down regulated and virions are not 
assembled (Depuydt et al., 2016). 
Infection of cervical epithelial cells within the transformation zone evolves through a stepwise 
progression of cytomorphological changes within host cells, termed CIN I-III (or low grade 
squamous intra-epithelial lesion/LSIL to high grade squamous intra-epithelial lesion/HSIL).  
HPV may exist episomally (as seen in non-malignant and pre-malignant tissue) or integrated 
within the host genome (largely seen in malignancies) (Cohen et al., 2019). 
CIN I/LSIL is characterised by the appearance of koilocytic changes predominantly within the 
upper epithelial layers together with increased nuclear:cytoplasmic ratios and vertical 
orientation of basal epithelial cells that occupies less than one third the thickness of the 
epithelium (Cohen et al., 2019).  Koilocytic atypia refers to the appearance of the host nucleus 
and includes nuclear enlargement with nuclear membrane irregularity and perinuclear halos.  
CIN II and III (HSIL) describe the progression of cellular atypia with dysplastic cells 
occupying less than two-thirds and full thickness of the epithelium, respectively.  Koilocytosis 
is not a feature in CIN III, reflecting the down regulation of HPV viral capsid proteins involved 
in disrupting host cellular cytoskeletal proteins.  Progressive accumulation of further genetic 
mutations is associated with development of invasive squamous cell carcinoma from CIN III. 
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Figure 1. 4 Diagram showing the development and progression of cervical intraepithelial 
neoplasia to invasive carcinoma (taken from Cohen et al., 2019) 
 
1.3 Local HPV genotype knowledge and the influence of HIV 
The development of HPV vaccines to provide immunity against lrHPV and hrHPV genotypes 
are based upon the most common genotypes associated with the development of cervical cancer 
in the developed world.  There is some concern that the hrHPV strains found most commonly 
in developed nations may not reflect the range seen in developing countries where cervical 
cancer burdens are greater.  In addition, the co-infection with HIV in women may result in 
different hrHPV genotype prevalence in high grade CIN or cervical carcinoma.  In many 
African countries, the local prevalence and genotypic spread of HPV is unknown (Bateman et 
al., 2015). 
Recent studies have shown that HIV-positive women carry a higher risk of infection with non-
HPV 16, non-HPV 18 high risk genotypes which may not be covered by currently available 
commercial vaccines (McDonald et al., 2012).  In addition, HIV-positive women carry a higher 
risk of infection with multiple HPV genotypes and infections are more likely to be persistent 
(Denny et al., 2014). 
 9 
Studies of HPV prevalence in HIV negative and positive South African men and women 
(Mbulawa et al., 2015) have shown: 
1. HPV prevalence of 36.7% in HIV negative women compared to 86.4% in HIV positive 
women. 
2. HPV prevalence decreased with increasing age in HIV negative women but not with HIV 
positive women. 
3. HIV positive women had a greater prevalence of one or more HPV genotypes compared 
to HIV negative women. 
HPV genotype analyses have been described for invasive cervical carcinoma in Zambian and 
Ugandan women (Odida et al., 2008; Bateman et al., 2015).  The Zambian study showed HPV 
16 and/or 18 genotypes in 69.9% of women.  The Ugandan cohort showed that the majority of 
women had a single infection (96.3%) and HPV 16 and 18 genotypes accounted for 80% of 
cases with single infection.  In general, women in Zambia and Uganda have similar hrHPV 
genotype profiles in cervical carcinoma and will likely benefit from the commercially available 
vaccines. 
A multicentre study that included women from South Africa, Ghana and Nigeria investigated 
the HPV prevalence and type distribution in invasive cervical cancer (Denny et al., 2014).  The 
HPV prevalence rate in invasive cervical carcinoma was 90.4% with the vast majority of 
women exhibiting a single infection (86.8%).  The prevalence of HPV infection and the 
presence of multiple HPV infections was higher in HIV-positive women, however the high rate 
of unknown HIV status in women from Ghana and Nigeria (96.9% and 82.1%, respectively) 
limited thorough analysis.  In contrast, only 11% of South African women had unknown HIV 
status. The most common HPV genotypes, in descending order were: 16, 18, 35, 45, 33 and 
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52.  With the high burden of HIV in sub-Saharan Africa and reports showing differing HPV 
genotype associations with cervix cancer, future vaccine design may be required to reflect these 
differences. 
1.4 Other HPV-associated carcinomas 
As anal, vulval, penile and head and neck cancers are also related to oncogenic HPV infection 
(Molijn et al., 2005; De Vuyst et al., 2013), vaccination has the potential benefit to also prevent 
these cancers.  Penile carcinomas, particularly the warty and basaloid subtypes are associated 
with HPV 16 and 18 genotypes.  Oropharyngeal squamous cell carcinoma (predominantly 
tonsillar and base of tongue) is associated with HPV 16 infection, together with smoking and 
alcohol (Mirghani and Blanchard, 2018).  Recent years have shown a sharp increase in the 
incidence of HPV-associated oropharyngeal carcinoma (Van Dyne et al., 2018).  HPV-
associated oropharyngeal carcinoma has been associated with improved disease-free survival 
post chemoradiation and surgery compared to HPV-negative oropharyngeal squamous cell 
carcinoma (Mirghani and Blanchard, 2018).  The implication of hrHPV 16 and 18 in non-
cervical carcinomas raises the possibility that vaccination may also provide benefit for the 
prevention of these HPV-related cancers.  This would mean widening the vaccination 
population to also include boys.  Data regarding the hrHPV genotype range in HIV-positive 
patients with penile, anal and oropharyngeal carcinoma is limited and is therefore an important 
area to investigate in populations with high HIV incidence, such as sub-Saharan Africa. 
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1.5 Methods employed for HPV DNA extraction and identification of hrHPV in 
clinical samples 
1.5.1 DNA extraction techniques 
Extraction of high quality DNA from fixed archival tissues poses a number of challenges.  The 
process of formalin fixation results in a number of crosslinks and DNA strand breaks (Kocjan 
et al., 2016).  This may interfere or completely inhibit subsequent amplification attempts by 
polymerase chain reaction (PCR).  In addition, unbuffered formalin is commonly used in some 
centres, increasing the risk of damaging the structural integrity of DNA.  Common steps for 
DNA extraction involve deparaffinisation with xylene, Proteinase K lysis followed by 
precipitation (or via another matrix) and reconstitution (Zhong et al., 2013).  Improvements in 
DNA extraction have been previously investigated and may be used if standard commercial 
extraction kits do not yield adequate amounts of DNA.  These additional methods include, but 
are not limited to:  
1.5.1.1 Heat treatment 
This is thought to partially reverse formalin DNA crosslinks.  This method has recently been 
successfully applied in the extraction of FFPE HPV DNA in a Zambian cross-sectional study 
where mean extracted nucleic acid concentration using heat methods (99C, 30 min) prior to 
xylene extraction was significantly higher than standard room temperature xylene extraction 
(117.4 ng/l versus 38.2 ng/l, p<0.001) (Bateman et al., 2015). 
1.5.1.2 Removal of the xylene deparaffinisation step 
Xylene is thought to inhibit PCR and removal of this step improves the yield of DNA extracted 
(Kocjan et al., 2016).  The xylene-free, prolonged proteinase K method of DNA extraction has 
been shown to allow amplification of a 650 bp fragment of human -actin DNA of in 100% of 
FFPE samples (Cannavo et al., 2012).  This amplicon size is much larger than those amplified 
by commercially available HPV SPF10 primers (65 bp) and GP5+/6+ (150 bp) primers. 
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1.5.1.3 Mineral oil 
A recent paper described efficient extraction of high quality DNA from archival FFPE samples 
using mineral oil for deparaffinisation (Heikal et al., 2014).  Paraffin dissolved in mineral oil 
is not thought to interfere with PCR (Lin et al., 2009).  Mineral oil also improved the time 
required for DNA extraction (20 min versus 75 min) and significantly reduced the number of 
centrifugation steps involved. 
 
1.5.2 Methods for detection of HPV and associated genotypes from extracted DNA 
1.5.2.1 PCR amplification of HPV DNA 
PCR amplification is conventionally performed using primers directed at HPV L1 gene 
sequences.  Commonly used primers include MY09/11, GP5+/6+ and SPF10 (Kleter et al., 
1998; Molijn et al., 2005; Micalessi et al., 2013; Kocjan et al., 2016) (Figure 1.5) which 
produce amplicons of varying lengths.  As the efficiency of PCR decreases with increasing 
amplicon base pair length, shorter sequences would theoretically have a higher success rate. 
 
 
Figure 1. 5 Diagram of HPV L1 consensus gene with various primers and products 
available for detection and amplification (taken from Molijn et al., 2005)  
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Detection of PCR product/amplicon is performed by size separation with electrophoresis and 
comparison of the size of the amplicon to standard DNA base pair ladder and positive control.  
The larger amplicons (150 and 450 bp) are separated by agarose gel electrophoresis while the 
50 bp amplicon would require polyacrylamide electrophoresis.  Visualisation of the double 
stranded amplicons depends on the electrophoresis method employed.  Intercalating 
fluorescent dyes (e.g., ethidium bromide) can be used for agarose and polyacrylamide gels with 
alternative silver precipitation methods available for polyacrylamide gels. 
 
1.5.2.2 Detection of specific HPV genotypes from PCR amplified consensus L1 ORF 
DNA 
For the detection of the specific HPV genotype, a number of commercial kits and sequencing-
based methods are available, which are described below:  
1.5.2.2.1 Line probe assay (LiPA) 
LiPA assays require the least amount of specialised equipment but have the advantage of low 
cost and simplicity (Figure 1.6).  HPV DNA is amplified by end point PCR using consensus 
sequence primers with inclusion of biotinylated dNTPs into the PCR reaction mix.  The 
biotinylated PCR product is then allowed to anneal to a solid matrix to which genotype-specific 
complimentary DNA sequences have been attached.  Complimentary binding of biotinylated 
DNA to specific hrHPV genotype sequences is detected using streptavidin-enzyme conjugate 
and chromogenic substrate (van den Brule et al., 2002; Molijn et al., 2005).  The identity of 
the specific hrHPV band is determined by comparing the position of the band with a standard 
chart. 
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Figure 1. 6 Diagram illustrating the principles of line probe assay (LiPA) chromogenic 
detection of HPV.  Biotinylated PCR product is annealed to immobilised specific HPV genotype 
sequences and detected using streptavidin-alkaline phosphatase system (A).  Identification of specific 
HPV genotypes is accomplished by comparing position of enzyme product band with standard positions 
(B) (taken from Molijn et al., 2005). 
 
1.5.2.2.2 Multiplex PCR 
Multiplex PCR systems make use of real time PCR (RT-PCR) and hydrolysis probe technology 
for detection of DNA target sequences (Kocjan et al., 2016).  Hydrolysis probes are 
oligonucleotide probes specific to the region of interest to be amplified but have two dyes 
covalently bonded to either end of the probe sequence (Figure 1.7).  The fluorophore (reporter 
dye) is covalently liked to the 5' end of the primer with a quencher dye attached to the 3' end.  
The close proximity of the reporter and quencher dye to each other ensures that no reporter 
fluorescence is emitted.  This transfer of energy between the reporter and quencher dyes is 
known as fluorescence resonance energy transfer (FRET).  During PCR, the 5'-3' exonuclease 
component of Taq polymerase removes the reporter dye from the annealed primer sequence 
and thereby separates it from the quencher dye (and therefore, FRET).  This results in the 
reporter dye emitting fluorescence when excited by light of the appropriate wavelength.  In this 
manner, a number of different probes, each with their unique reporter-quencher dye 
 15 
combination can be added to a single DNA template and different sequences detected in the 
same sample by using different wavelength channels for detection. 
 
 
Figure 1. 7 Diagram outlining the principles of real time PCR (RT-PCR).  Before PCR 
amplification occurs, the probe reporter dye fluorescence is absorbed by a nearby quencher by the 
process for fluorescence resonance energy transfer (FRET), thereby producing no detectable 
fluorescence in the emission spectrum of the reporter dye.  Once PCR begins (at the 3' end of the 
separate primer) and Taq polymerase 5'-3' exonuclease activity releases the reporter dye from the 5' end 
bound probe, FRET cannot persist over wider distances and the report dye fluorescence can be detected 
(taken from http://ipc.nxgenomics.org/teaching/qpcr/qpcr.html). 
 
In a RT-PCR protocol, fluorescence is detected during the extension phase of each cycle 
throughout the PCR (i.e., in real time).  The fluorescence trace is roughly sigmoid in shape.  
The threshold cycle (Ct) refers to the cycle number at which the trace begins to rapidly increase 
in intensity (exponential phase) and crosses the threshold (i.e. increases in intensity above that 
of background) (Figure 1.8).  Ct is a relative measure of the concentration of the target DNA 
within the sample. 
 
 16 
 
Figure 1. 8 Fluorescence curve for the ideal RT-PCR reaction.  Diagram showing the curve 
obtained from an ideal RT-PCR reaction. The threshold cycle (Ct) is the cycle number at which the 
reporter dye fluorescence is greater than background.  After this Ct has been reached, the increase in 
fluorescence enters an exponential phase until it plateaus.  Rn = increment in fluorescence signal at 
each time point (Image taken from http://www.ncbi.nlm.nih.gov/probe/docs/techqpcr/). 
 
1.5.2.2.3 Melting curve analysis 
Melting curve analysis allows for the detection of multiple PCR products using various 
combinations of limited fluorescent dyes and take advantage of changes in fluorescence that 
occurs when double stranded DNA is denatured at high temperatures and allowed to reanneal 
in an environment of slowly cooling temperature.  Either fluorescent dyes attached to probes 
or an intercalating dye (e.g., SYBR® Green) can be used, the latter showing fluorescence only 
when intercalated between annealed, double stranded DNA and not single stranded DNA.  An 
example of melting curve analysis product for hrHPV identification is PapillomaFinder 
SMART20 (Ossel et al., 2014) (Figure 1.9).  HPV DNA is enriched in the sample by PCR 
amplification using universal forward and reverse primers (Step 1).  Probe pairs (5'/green and 
3'/black) are annealed to the amplicons and ligated using Taq ligase.  The red region is a stuffer 
sequence complimentary to the genotype specific probe.  The blue and brown regions are target 
specific regions of the probe (Steps 2 and 3).  The ligated probes are amplified using universal 
primers with the 5' primer containing FAM dye (Step 4).  ROX and Cy5 labelled detection 
probes are added and produce fluorescence via FRET if hybridised to their complimentary 
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stuffer sequence in close proximity to FAM.  Owing to the difference in nucleotide sequences 
between genotypes, the annealed probe-stuffer sequence duplex will melt/denature at different 
temperatures, resulting in loss of FRET and therefore fluorescence.  The negative derivative of 
the change of fluorescence is plotted against temperature change.  Combination of dyes and 
differing melting temperatures results in detection of multiple genotypes in a single tube. 
 
Figure 1. 9 Detection of multiple hrHPV genotypes simultaneously using melting curve 
analysis 
 
1.5.2.2.4 Genotype specific primers and Sanger dideoxynucleotide sequencing 
It is possible to design genotype specific primers by comparing L1 ORF hrHPV DNA 
sequences by alignment methods (Gharizadeh et al., 2005).  Detection of non-overlapping 
regions have to however be aligned against nucleotide databases to ensure non-overlap with 
other viral or human gene targets.  Sanger dideoxynucleotide (ddNTP) sequencing is based on 
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the principle of DNA chain termination during PCR using ddNTP analogues of all dNTPs, each 
also containing a fluorescent dye.  ddNTPs are incorporated into the DNA chain synthesised 
by Taq polymerase and once incorporated, prevent further elongation.  The variably sized PCR 
products, each with one of four ddNTP fluorophores are separated by size electrophoresis and 
the dyes detected by laser.  The sequence of the PCR product can then be read out from 5'-3', 
one nucleotide at a time (Figure 1.10).  This method was used in this study. 
 
 
 
Figure 1. 10 Sanger dideoxynucleotide chain termination method of DNA sequencing.  A target 
sequence is amplified from a forward primer with a mixture of dye-labelled dideoxynucleotides 
(ddNTPs) mixed with normal unlabeled deoxynucleotides (dNTPs).  Competition of ddNTPs and 
dNTPs occur during the PCR extension step.  Once a complimentary ddNTP is incorporated, the 
sequence is terminated as a phosphodiester bond cannot be created with the next dNTP.  Varying lengths 
of terminated chains with dye labels are produced and separated by size using capillary electrophoresis.  
As the dye labelled strands pass a laser, the fluorescence peak generated corresponds to the specific 
ddNTP.  Each strand differs in size by a single nucleotide corresponding to the target DNA sequence 
(5' to 3') (Image taken from http://www.orbitbiotech.com). 
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1.5.2.2.5 Next generation sequencing 
This is also known as high throughput sequencing or massive parallel sequencing.  It 
encompasses a number of different methodologies with the common feature of simultaneous 
sequencing of multiple DNA sequences.  These methodologies include sequencing by synthesis 
(NextSeq [Illumina®]), semiconductor sequencing (Ion Torrent™ [Thermo Fisher Scientific]) 
and pyrosequencing (454 [Roche]) (Radford et al., 2012).  An article exploring the use of next 
generation sequencing in the context of HPV in a local (Cape Town) population showed that 
hrHPV genotypes were identifiable via this technology which were not detected by commercial 
kits (Meiring et al., 2012).  At present, access to this technology is limited and prohibitively 
expensive for routine diagnostic use. 
The associated advantages and disadvantages of each hrHPV detection technique are tabulated 
below (Table 1.1). 
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Table 1. 1 Various modalities available for hrHPV genotype identification 
HPV genotype 
detection system 
Advantages Disadvantages 
Line probe assay 
(LiPA) 
Cheap, multiple genotypes detection 
simultaneously. No need for additional 
equipment apart from endpoint PCR 
machine (i.e., RT-PCR setup, DNA 
sequencer). 
Chromogenic substrate system, 
time consuming.  Each sample 
requires separate strip for 
development.  Bands fade over 
time. 
Multiplex RT-
PCR 
Detection of multiple hrHPV genotypes 
within a single tube using different 
fluorophore spectral features. 
Requires RT-PCR equipment 
with multiple fluorophore 
filters.  Expensive. 
Melting curve 
analysis 
Potential for simultaneous detection of 
multiple hrHPV genotypes within a single 
reaction tube 
As for multiplex RT-PCR.  
Multiple steps involved for 
probe ligation/PCR.  Require 
appropriate software for 
interpretation of melt curve 
profile. 
Sanger 
dideoxynucleotide 
DNA sequencing 
Quick, relatively inexpensive.  No 
additional expertise required for analysis of 
DNA sequence results. 
Multiple single reactions 
required.  Require non-
overlapping genotype specific 
DNA sequences for primer 
design. 
Next generation 
sequencing 
Identification of hrHPV genotypes 
otherwise not identified by other techniques. 
High cost, requires specialised 
equipment and technical skills 
for data analysis. 
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1.5.3 HPV genotyping at Anatomical Pathology, GSH 
 
Currently, no HPV genotyping platform is present in the Division of Anatomical Pathology, 
Groote Schuur Hospital for FFPE tissue specimens or cytology specimens (Pap smears). 
 
At present, HPV-related cancers are identified using the surrogate marker, p16. P16 (also 
known as p16INK4a) is a tumour suppressor gene that plays a role in control of the cell cycle by 
inhibiting cyclin dependant kinase and preventing progression of G1 to S phase. This protein 
is overexpressed as a response to destruction of p53 and Rb via HPV proteins E6 and E7.  
Increased p16 expression therefore is a surrogate for hrHPV-related carcinogenesis.  P16, 
however is not hrHPV-specific and can be upregulated in a number of high grade malignancies 
(e.g., high grade serous carcinoma of the endometrium).  P16 expression also does not provide 
information regarding the specific hrHPV genotype. 
 
Alternative methods for hrHPV detection is fluorescence in situ hybridisation (FISH) which  
currently only tests for HPV 16 and 18 (Kobayashi et al., 2018).  This technology, though 
sensitive, is time consuming and is not well suited for screening multiple samples 
simultaneously.  
 
Knowledge of HPV status of tumours is becoming increasingly important as HPV+ tumours 
are associated with better prognosis especially in the context of head and neck cancers 
(Kobayashi et al., 2018).  Therefore, a need exists for extraction of high quality DNA from 
FFPE tissue and accurate, sensitive detection of hrHPV genotypes in cancer samples.  This 
project aims to use commercially available kits for DNA extraction and detection of hrHPV 
genotypes using RT-PCR technology as this allows for the simultaneous, real time detection 
of multiple hrHPV genotypes in multiple samples.  This has a potential advantage over 
traditional colorimetric assays such as LiPA in terms of shortened time required and digital 
output of results for immediate analysis via downstream software programs e.g., MSExcel.  
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As the incidence of HPV-related malignancies (particularly oropharyngeal carcinomas) is 
increasing rapidly in developed countries, the need for hrHPV detection is likely to increase. 
 
In the context of cervical carcinoma, hrHPV genotyping is of particular importance especially 
in precursor lesions (SIL) and in routine cytology (Pap smears).  hrHPV detection in Pap 
smears has the potential to reduce pathologist and cytologist workloads, increase productivity 
and rapidly streamline patients to colposcopic clinics.  hrHPV detection has the further 
advantage of reducing the number of cases diagnosed as ASC-H (atypical squamous cells, 
cannot exclude high grade SIL), thereby reducing potentially unnecessary colposcopy visits 
(+/- biopsy) or repeated Pap smears. 
 
This study is intended as a pilot study for the investigation of the feasibility of using FFPE 
tissue for the detection of hrHPV in cervical carcinoma specimens.  For this purpose, only cases 
with high tumour burdens were chosen.  Based on the success of the high burden cases, 
screening of the entire cohort would be performed together with testing other HPV related 
tumours.  Future application to cervical Pap smears could be considered if the RT-PCR 
platform is successful. 
 
1.6 Aims and objectives of the current study 
1. To identify HPV DNA, by polymerase chain reaction (PCR) using HPV L1 consensus 
primers, in a cohort of cervical cancer patients diagnosed at GSH.   
2. To determine the specific HPV genotype/s in each sample by using a commercially 
available real-time PCR kit.   
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Ethics approval 
The protocol was approved by the Human Research Ethics Committee (HREC) of the Faculty 
of Health Sciences, UCT (HREC reference number: 247/2016).  The ethics approval was 
renewed annually for the duration of the study. 
 
2.2 Study design 
This was a retrospective study in the Division of Anatomical Pathology.  Funding was received 
from the National Health Laboratory Service (NHLS) Research Trust. 
 
2.3 Case selection 
The sample population chosen for this study is the same as that of Dr G Skead (Division of 
Anatomical Pathology, Groote Schuur Hospital/NHLS) (Skead, 2016).  Dr Skead’s study 
required samples demonstrating both SIL and invasive cervical squamous cell carcinoma on 
paraffin wax blocks in sufficient quantity for construction of tissue microarrays. 
 
These cases were identified by a search of the NHLS DISA database in the division of 
Anatomical Pathology, Groote Schuur Hospital (Laboratory Systems Technologies, SA).  The 
following criteria were used to select cases: excision specimens (including LLETZ, cone 
biopsy and hysterectomy) of primary cervical squamous cell carcinoma with normal 
epithelium, HSIL and invasive carcinoma in the same case.  Exclusion criteria included 
superficially invasive carcinoma, non-squamous carcinomas, metastatic tumours, biopsies with 
insufficient material and any case where tissue extraction would result in loss of diagnostic 
material.  HIV status was obtained from DISA results or from the clinical history provided on 
the histology request form.  Information of each case (date, age, number of blocks) was entered 
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into a Microsoft Excel spreadsheet.  The cases were arranged in temporal sequence and each 
SCA number given a new numerical designation.  Names were removed to ensure patient 
confidentiality. 
 
Slides and paraffin blocks from 2004-2014 were retrieved from archives.  The diagnoses were 
reviewed with haematoxylin and eosin (H&E)-stained slides.  From the original number of 
records of squamous cell carcinoma (284 cases), a total of 57 cases were chosen for Dr Skead’s 
study.  Many of the original 284 cases were duplicated cases (biopsies and excision) and 
biopsies were unsuitable. 
 
In this pilot study, of the 57 cases, 23 contained sufficient tumour burden (>75% surface area) 
for optimal DNA extraction and further.  The remaining 34 cases (demonstrating smaller 
tumour burden) were planned to be extracted in the future (not part of this MMed thesis) to 
reach the total of 57. 
 
2.4 Sectioning of tissue for DNA extraction 
For each case, four sections of 4 m thickness were cut on a rotary microtome.  Since all the 
tissue blocks represented tumour only, the sections were immediately placed into a 1.5 ml 
microcentrifuge tube.  Between blocks, various means were employed to reduce cross-
contamination of sample DNA.  These included using a new microtome blade used for each 
block, wiping down the microtome with xylene and ethanol, sectioning paraffin-only blocks 
(negative DNA control) at end of each sectioning session.  Further, filtered micropipette tips 
were used for all pipetting steps during DNA extraction and PCR. 
 
2.5 DNA extraction and quantitation 
DNA was extracted from FFPE tissue using the QIAamp DNA FFPE Tissue kit (Qiagen Inc., 
Valencia, CA, USA) according to the manufacturer’s guidelines. 
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Briefly, to each of the labelled tubes containing the tissue, tissue sectioning controls and DNA 
extraction negative control, 600μl of xylene was added.  The tubes were vortexed vigorously 
and then incubated for 5 minutes at room temperature (RT).  Thereafter, 300μl of ethanol (96-
100%) was added to each tube and vortexed.  The tubes were centrifuged at full speed (13 
000rpm) for 2 minutes at RT.  The supernatant was removed without disturbing the pellet.  
Nine hundred microlitres of ethanol (96-100%) was added to each tube and vortexed.  The 
samples were centrifuged at full speed for 2 minutes at RT.  The supernatant was removed 
without disturbing the pellet. 
The open microcentrifuge tube was incubated at 37oC on a Dri-block DB-3 (Bio-Techne, 
Minneapolis, MN, USA) until the ethanol had evaporated.  One hundred and eighty microlitres 
of buffer ATL and 20µl Proteinase K were added to each tube and vortexed.  The samples were 
incubated at 37oC overnight.  The next morning, the samples were removed from the heating 
block and the heating block was set to 90°C.  Parafilm was wrapped over the microcentrifuge 
caps.  The tubes were incubated for 1 hour at 90°C in order to partially reverse formaldehyde 
modification of nucleic acids and deactivate Proteinase K activity.  The tubes were briefly 
centrifuged to remove drops from the inside of the lids.  Two hundred microlitres of buffer AL 
and 200 µl ethanol (100%) were added to the sample and mixed by pipetting to yield a 
homogenous solution.  This mixture was added to labelled assembled QIAamp® MinElute 
columns and 2 ml collection tubes without wetting the rim of the columns.  The tubes were 
capped and centrifuged at 8000 rpm for 1 minute.  The filtrate and collection tubes were 
discarded and the column placed in new 2 ml collection tubes.  Five hundred microlitres of 
buffer AW1 was added to the columns without wetting the rim, capped and centrifuged at 8000 
rpm for 1 minute.  The filtrate and collection tubes were discarded and the column placed in 
new 2 ml collection tubes.  Five hundred microlitres of buffer AW2 was added to the columns 
without wetting the rim, capped and centrifuged at 8000 rpm for 1 minute.  The filtrate and 
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collection tubes were discarded and the column placed in new 2 ml collection tubes.  
Thereafter, the columns were centrifuged at full speed (13000 rpm) for 3 minutes to eliminate 
buffer carry over.  The columns were placed in a clean labelled 1.5 ml microcentrifuge tube.  
Twenty seven microlitres of sterile water was added carefully to the columns, incubated at RT 
for 5 minutes and centrifuged at 13 000 rpm for 1 minute.  This sterile water step was repeated 
once.  The eluted DNA was either used immediately in the next step or stored at -20oC. 
 
2.6 DNA spectrophotometry 
The quality and quantity of the extracted DNA was assessed using the NanoDrop™ OneC 
system (Thermo Fisher Scientific Inc., Waltham, MA, USA) (Appendix 1). 
 
2.7 Reference gene PCR 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was amplified to assess the 
quality of extracted DNA.  The QIAGEN HotStarTaq Master Mix kit (Qiagen Inc., Valencia, 
CA, USA) was used according to manufacturer instructions.  Briefly, all solutions were thawed 
gently vortexed and kept on ice until required.  The master mix was made up as per Table 2.1.  
The volumes for one reaction was multiplied to the appropriate number of reactions, including 
controls.  Twenty three  microlitres of the master mix was aliquoted into labelled 0.2 ml PCR 
tubes.  Thereafter, 2 l of sample DNA (100 ng) was added to each tube. A previously tested 
sample was used as a positive control.  Two negative controls were used included to monitor 
cross-contamination/spill  during PCR setup.  This included a tissue sectioning control which 
comprised a paraffin wax block sectioned at the end of the samples to exclude DNA cross 
contamination and a DNA extraction control. 
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PCR was performed on a GeneAmp® PCR system 9700 (Applied Biosystems, Foster City, CA, 
USA).  The conditions for this PCR are listed in Table 2.2 and the primer sequences are listed 
in Table 2.3. 
 
Table 2. 1 PCR Master mix recipe for housekeeping gene 
PCR component Volume (l) 
HotStarTaq® Master mix (2x) 12.5 
Forward primer (150 ng/l) 0.5 
Reverse primer (150 ng/l) 0.5 
Sterile water 9.5 
gDNA template (100 ng) 2 
Total 25 
 
Table 2. 2 End point PCR for housekeeping gene amplification  
PCR step Condition 
Activation 95C/15 min 
Denaturation (39 cycles) 94C/20 sec 
Anneal (39 cycles)  60C/20 sec 
Extension (39 cycles) 72C/20 sec 
Final extension 72C/5 min 
Hold 4C/ 
 
2.8 HPV L1 primer synthesis  
GP5+/GP6+ primers were synthesised on an Applied Biosystems 394 DNA synthesiser at the 
Department of Molecular & Cellular Biology, University of Cape Town (UCT) (Applied 
Biosystems, Foster City, CA, USA) (Table 2.3).  The primers were diluted in water and added 
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to the master mix to yield final concentrations of 0.5-1 µM.  Primer stock and dilutions were 
stored at -20°C. 
 
Table 2. 3 Primer sets used in the amplification of housekeeping gene and HPV L1 
consensus gene  
Primer set DNA sequence (5'-3') Product size (bp) 
GAPDH (forward) 
GAPDH (reverse) 
AGGTCATCCATGACAACTTTGGTATC 
TGAGGCCCTGCAGCGTACTC 
222 
GP5+ (forward) 
GP6+ (reverse) 
TTTGTTACTGTGGTAGATACTAC 
GAAAAATAAACTGTAAATCATATTC 
150 
 
2.9 Optimisation of HPV L1 consensus sequence endpoint PCR using GP5+/GP6+ 
primers 
The HotStartTaq master mix was made up as per Table 2.1.  The volumes for one reaction was 
multiplied to the appropriate number of reactions, including controls.  Twenty three microlitres 
of the master mix was aliquoted into labelled 0.2 ml PCR tubes.  Thereafter, 2 l of sample 
DNA (100 ng) was added to each tube.  PCR was performed on a GeneAmp® PCR system 
9700 (Applied Biosystems, Foster City, CA, USA). 
 
The following parameters were subject to optimisation for this PCR (Table 2.4): 
 
1. Amplification conditions 
The initial experiment used standard PCR cycling parameters.  Run 2 reduced the 
annealing temperature from 50C to 40C as the melting temperature (Tm) of the 
GP5+/GP6+ primers are low (45°C and 41°C, respectively) (Evans et al., 2008).  Run 
3 kept the temperatures constant but extended the duration of annealing and extension 
from 30 seconds to 2 minutes (Table 2.4). 
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2. Magnesium titration 
In Run 3, the MgCl2 concentration was increased from 1.5 mM to 3.0 mM by addition of 
stock 25 mM MgCl2 (Table 2.4).  The volume of  sterile water was adjusted accordingly 
to keep the final volume of the PCR mix at 25 l (Table 2.1). 
 
Table 2. 4 End point PCR optimization for HPV L1 amplification by GP5+/GP6+ primers 
PCR step Initial run Run 2 Run 3 
Activation 95C/15 min 95C/15 min 95C/15 min 
Denaturation (39 cycles) 94C/30 sec 94C/30 sec 94C/30 sec 
Anneal (39 cycles) 50C/30 sec 40C/30 sec 40C/2 min 
Extension (39 cycles) 72C/30 sec 72C/30 sec 72C/2 min 
Final extension 72C/5 min 72C/5 min 72C/5 min 
Hold 4C/ 4C/ 4C/ 
 
2.10 Reamplification endpoint PCR of HPV L1 gene using GP5+/GP6+ primers 
To increase the sensitivity of this PCR, reamplification was performed.  This is akin to a 
“nested PCR” except the same primer set is used in a second round of PCR.  The PCR master 
mix was the same as for Run 3 except that two microlitres of the first PCR reaction was used 
as the new template. 
 
2.11 Touchdown PCR optimisation using GP5+/GP6+ primers 
A published method for improved detection of HPV L1 gene using GP5+/GP6+ primers using 
a touchdown technique was used (Evans et al., 2005).  This modified PCR protocol involved 
reducing the annealing temperatures in 0.5C decrements per cycle and increasing total cycles 
to 50 (Table 2.5).  The PCR conditions were further optimised by titration of genomic DNA, 
primer concentrations and MgCl2 concentrations as follows: 
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Genomic DNA template:  50, 100, 250 and 500 ng 
Primer concentration:   0.5 M and 1.0 M 
MgCl2 concentration:   1.5 mM and 4.0 mM 
 
Table 2. 5 Touchdown PCR setup for HPV L1 amplification by GP5+/GP6+ primers 
Touchdown PCR step Conditions 
Activation 95C/15 min 
Denaturation (21 cycles) 94C/2 min 
Anneal (21 cycles) 50C/2 min to 40C/2 min, 
decreasing 0.5C/cycle 
Extension (21 cycles) 72C/1.5 min 
Denaturation (29 cycles) 94C/2 min 
Anneal (29 cycles) 40C/2 min 
Extension (29 cycles) 72C/1.5 min 
Final extension 72C/4 min 
Hold 4C/ 
 
2.12 Application of optimised GP5+/GP6+ HPV L1 touchdown PCR conditions to all 
extracted samples 
Extracted DNA from all the cases were amplified using the optimised touchdown protocol with 
100 ng template gDNA, 0.5 M forward and reverse primers and 4 mM MgCl2. 
 
2.13 DNA agarose electrophoresis 
Post PCR DNA samples were size separated on a 1.5 % agarose gel (Appendix 2).  The running 
buffer used was 1xTBE (Appendix 2).  PCR products  were prepared by mixing 10 l of each 
with bromophenol blue loading dye (1 µl; Appendix 2) and dispensed into separate wells of 
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the gel.  Five microliters of a ready-to use molecular weight marker, HyperLadder™ 100 bp 
(Bioline, London, UK) was also included.  This ladder produces bands ranging from 100-1300 
bp.  The gel was run at 100V (constant) for 60-90 min.  The gel was visualised by UV 
transillumination and images were captured digitally via GeneSnap software (Syngene, 
Cambridge, UK) in the Division of Forensic Medicine, UCT.  The images were saved in either 
tiff or png formats. 
 
2.14 Detection of hrHPV genotypes by multiplex real time PCR (RT-PCR) 
Detection of hrHPV genotypes was performed using Sacace HPV Genotypes 14 Real-TM 
Quant Kit (Como, Italy) which uses hydrolysis probe technology to simultaneously detect up 
to 14 hrHPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) with additional 
probes included as positive controls (-globin).  The HPV target sequences for this kit are 
within the E6 and E7 genes and not L1 as used in the end point PCR experiments.  This kit is 
optimised for cervical swabs, fluid cytology and mucosal biopsy material.  It has also been 
successfully used on DNA extracted from FFPE tissue (Zohoncon et al., 2016, Snietura et al., 
2017). 
 
The hydrolysis probes included FAM (HPV 16, 33, 39 and 58), JOE (HPV 31, 35, 45 and 52), 
ROX (HPV 18, 59, 66 and 68) and Cy5 (internal control [-globin], HPV 51 and 56). 
 
Table 2. 6 Absoprtion and emission spectra of dyes with available filter set 
Fluorophore Excitation 
wavelength 
Emission 
wavelength 
LightCycler™ 480 II filter set 
available 
FAM 495 nm 520 nm 498/580 nm 
JOE 529 nm 555 nm 533/610 nm 
ROX 575 nm 602 nm 533/610 nm 
Cy5 617nm 667 nm 618/660 nm 
 
 32 
A stock solution of Taq polymerase (“Hot Start DNA polymerase” ) and buffer was made by 
adding 600 l PCR buffer mix to 60 l Hot Start DNA Polymerase.  This mixture, called “PCR-
buffer-FRT”, was briefly vortexed and kept on ice.  The total volume of each of the 4 DNA 
probe mixes required was calculated according to the number of samples using the formula 
10xN+2 (where N=number of samples for analysis) while the total volume of master mix DNA 
polymerase was 5xN+2. 
 
Thawed extracted gDNA from each case was diluted with sterile water to a final concentration 
of 20 ng/µl and kept on ice until required.  The reaction consisted of 10 µl (containing 200 ng) 
gDNA with 15 µl PCR-buffer-FRT.  The total reaction volume was 25 µl (Table 2.6). 
 
The samples were dispensed into LightCycler™ 480 96 multi-well white plates (Roche, Basel, 
Switzerland).  The plates were sealed with clear adhesive film to reduce evaporation.  Negative 
controls included no template DNA.  Positive controls (provided in the kit) corresponding to 
1000 genome equivalents/ml included all hrHPV genotypes and human -globin.  RT-PCR 
was performed on a LightCycler™ 480 II (Roche, Basel, Switzerland) instrument housed in 
the Division of Immunology, UCT Medical School. 
 
Table 2. 7 Recipe for Sacace RT-PCR kit 
 
PCR component Volume (l) 
PCR-buffer-FRT mix 15 
gDNA template (200 ng) 10 
Total 25 
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LightCycler™ 480 1.5.1.62 SP3 software was used with the following parameters: 
 Detection format: 4 color hydrolysis probe. 
 Workflow: Abs quant. 
 Filter combinations: 498-580 nm (FAM), 533-610 nm (Red 610), 618-660 nm (Cy5). 
 
The RT-PCR parameters used were those provided with the Sacace kit: 
 
Table 2. 8 RT-PCR conditions for multiplex identification of hrHPV genotypes 
PCR step Condition Ramp rate  
Activation 95C/15 min 4.4C/sec 
Denaturation (5 cycles) 95C/5 sec 4.4C/sec 
Annealing (5 cycles) 60C/20 sec 2.2C/sec 
Extension (5 cycles) 72C/15 sec 4.4C/sec 
Denaturation (40 cycles) 95C/5 sec 4.4C/sec 
Annealing (40 cycles) 60C/20 sec 2.2C/sec 
Extension (40 cycles with 
fluorescence acquisition) 
72C/15 sec 4.4C/sec 
Hold 40C/30 sec 4.4C/sec 
 
The data was analysed by selecting “Abs quant/2nd derivative max” for all samples.  The raw 
fluorescence data and calculated Ct values were exported (in .txt format) and analysed with 
Microsoft Excel 2016. 
 
2.15 Confirmation of hrHPV genotypes by DNA sequencing and BLAST alignment 
DNA sequencing was performed to both confirm the L1 DNA sequence of the GP5+/GP6+ 
PCR products and to verify the hrHPV genotypes of samples that showed positive results in 
the overlapping filter spectra only. 
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The GP5+/GP6+ PCR products for cases 20 and 23 were randomly chosen for confirmation of 
hrHPV L1 DNA sequence as no separate positive control was available.  The GP5+ forward 
primer was used for this purpose.  DNA sequencing (via Sanger method) was performed by 
Inqaba Biotechnical Industries (Pretoria, South Africa) on an ABI3500XL system (Applied 
Biosystems, Foster City, CA, USA).  
 
Genotype-specific forward sequencing primers were synthesised for cases 33, 34, 42 and 55 
using sequences previously described by Gharizadeh et al., (2005) as these cases showed 
potential overlap with types 18/31 and 45/59.  The primer sequences were: HPV 18 (5'-
GCTTCTACACAGTCTCCTGT-3'), HPV 31 (5'-GTGCTGCAATTGCAAACAGT-3'), HPV 
45 (5'-TATGTGCCTCTACACAAAAT-3').  A genotype specific primer for HPV 59 was not 
described in this paper.  It was reasoned that if the HPV 45 sequencing produced no positive 
results, a separate HPV 59 specific probe would be designed and tested.  The forward 
sequencing primers were synthesised and used for Sanger sequencing at Inqaba Biotechnical 
Industries (Pretoria, South Africa). 
  
The resultant nucleotide sequences were generated in abi file format converted into FAST-all 
(FASTA) format using BioEdit, a freeware biological sequence alignment edit programme 
(Carlsbad, CA, USA).  The FASTA-formatted DNA sequences were subjected to Basic Local 
Alignment Search Tool (BLAST) analysis using the National Center for Biotechnology 
Information (NCBI) nucleotide BLAST service (http://blast.ncbi.nlm.nih.gov).  The “other -
nucleotide” database was selected and the search was optimised for highly similar sequences 
(megablast). 
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CHAPTER THREE 
RESULTS 
 
3.1 Sample group 
3.1.1 Patient demographics 
The cohort comprised 23 cases.  The most common age range was 40-49 years.  Only 1 case 
of cervical squamous cell carcinoma was present in each of the extreme age ranges 20-29 and 
70-79 (Figure 3.1). 
 
  
Figure 3. 1 Number of cases of cervical squamous cell carcinoma per age group 
 
3.1.2 HIV distribution within cases  
Two cases were HIV-positive, 14 HIV-negative and 7 HIV unknown (i.e., the status could not 
be determined from DISA lab investigations or from the clinical history provided on the 
specimen submission form). 
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3.2 DNA extraction from FFPE archival tissue 
The average concentration of extracted gDNA was 463.2 ng/l (range: 91.3-791.4) (see 
Appendix 2.  The average A260/A280 ratio was 1.86 (range: 1.67-1.94) with a median of 1.88.  
A calculated A260/A280 ratio  1.80 is generally considered adequate purity (Wilfinger et al., 
1997).  The majority of cases (20/23, 87%) were of optimal purity, with cases 15, 26 and 51 
achieving A260/A280 ratios of 1.67, 1.78 and 1.67, respectively. A ratio lower than 1.8 may 
indicate the presence of proteins or other contaminants but these marginally suboptimal values 
did not appear to negatively affect downstream PCR reactions. 
 
3.3 Endpoint PCR 
3.3.1 Housekeeping gene PCR using reference gene primers 
All samples showed amplification for GAPDH (results not shown).  This indicated that the 
sample DNA was free of inhibitors and was of sufficiently good quality to proceed with the 
GP5+/6+ PCR and RT-PCR.  The negative controls showed no amplification indicating that 
there were no cross-contamination events. The positive control amplified a band of the correct 
size (either 150 bp or 222 bp) suggesting that the PCR conditions were optimal.  Some 
reduction in intensity of PCR amplicons was noted in the oldest specimen (case 3 from 2004, 
Figure 3.2 lanes 2 and 7) compared to the most recent (case 56 from 2014, Figure 3.2 lanes 4 
and 9).  Cases from approximately midpoint of the time range showed similar intensity to that 
obtained from 2014 (case 19 from 2008, Figure 3.2 lanes 3 and 8).  This difference was likely 
due to increased DNA degradation over time however subsequent endpoint PCR experiments 
showed no such reduction in HPV L1 amplification (Figure 3.5).  Therefore, it may be 
suggested that DNA fragmentation was more significant in housekeeping gene regions 
compared to HPV L1 sequences.  
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Figure 3. 2 DNA electrophoresis of selected cases amplified by end-point PCR using GAPDH 
housekeeping primers.  Positive PCR amplicon = 222 bp (right arrow).  Lane 1: 100 bp molecular 
weight marker ladder, lane 2: Case 3 (year 2004) (50 ng gDNA), lane 3: Case 19 (year 2008) (50 ng 
gDNA), lane 4: Case 56 (year 2014) (50 ng gDNA), lane 5: GAPDH positive control, lane 6: negative 
control, lane 7: Case 3 (100 ng gDNA), lane 8: Case 19 (100 ng gDNA), lane 9: Case 56 (100 ng 
gDNA), lane 10: GAPDH positive control, lanes 11 and 12: negative controls. 
 
3.3.2 HPV L1 end point PCR using GP5+/GP6+ primers 
Standard and modified PCR experiments failed to produce a 150 bp L1 amplicon in cases 3, 19 
and 56 (results not shown).  Reasons for this included suboptimal PCR conditions as no positive control 
was available and that the amount of HPV DNA in the samples may be below the detection limit. 
To increase the sensitivity of this PCR a nested PCR ( reamplification PCR) was performed. 
 
3.3.3 Reamplification HPV L1 end point PCR using GP5+/GP6+ primers 
Reamplification PCR was performed on the same selected cases representing either time 
extreme plus one midpoint as shown in Figure 3.2.  Interestingly, the oldest specimen (case 3, 
year 2004) produced the brightest amplicon (Figure 3.3, lane 2).  This may reflect a greater 
HPV burden than case 19 (year 2008) which showed a fainter band (Figure 3.3, lane 3) .  The 
most recent case, 56, (year 2014) showed no amplification (Figure 3.3, lane 4).  The bands 
visible below 100 bp in lanes 3-5 are primer dimer bands and do not represent HPV L1 
amplicons.  
 
Reamplification PCR proved that HPV L1 DNA sequences could be detected in samples with 
sufficient HPV burden.  Reamplification PCR is, however, time consuming by requiring two 
PCR runs and more costly with enzymes and reagents as each case effectively requires twice 
  1          2        3        4         5          6        7        8          9        10       11      12  
300 bp 
200 bp 
100 bp 
Lane 
222 bp 
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the amount.  Therefore, a published touchdown PCR protocol was optimised to permit L1 
detection in one run. 
 
 
Figure 3. 3 DNA electrophoresis of selected cases amplified by reamplification end-point 
PCR using GP5+/GP6+ HPV L1 primers.  Positive PCR amplicon = 150 bp (right arrow).  Lane 1: 
100 bp molecular weight marker ladder, lane 2: Case 3 (100 ng initial gDNA), lane 3: Case 19 (100 ng 
initial gDNA), lane 4: Case 56 (initial 100 ng gDNA), lane 5: negative control. 
 
3.3.4 Touchdown PCR optimisation of HPV L1 using GP5+/GP6+ primers 
Optimisation of the published touchdown protocol was performed in order to maximise the 
detection of HPV within cervical squamous cell carcinoma specimens.  No modifications to 
the PCR parameters were made however a dilution series of genomic DNA was performed in 
order to determine the detection limits of the method and to further conserve gDNA for 
downstream hrHPV RT-PCR investigations.  Primer concentrations and MgCl2 concentrations 
were modified to maximise the efficiency and yield of the PCR reaction.  Case 3 was chosen 
for this optimisation as it demonstrated adequate amount of amplifiable HPV L1 DNA in the 
reamplification experiment and theoretically contained the gDNA with the greatest degree of 
degradation (as noted in reference gene experiments, Figure 3.2). 
 
Touchdown PCR demonstrated HPV L1 gene product could be detected with as low as 50 ng 
gDNA template (Figure 3.4, lanes 19-22).  Primer concentration did not affect PCR product 
yield however 4.0 mM MgCl2 resulted in improved PCR product yield versus 1.5 mM, 
especially at lower gDNA concentrations of 100 and 50 ng (Figure 3.4 lanes 18 and 20, 
respectively). 
300 bp 
200 bp 
100 bp 
Lane      1                2             3                 4                 5   
150 bp 
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Figure 3. 4 DNA electrophoresis of optimised touchdown end-point PCR using GP5+/GP6+ 
HPV L1 primers.  All samples are from case 3.  Positive PCR amplicon = 150 bp (right arrow).  Lanes 
1 and 12: 100 bp molecular weight marker ladder, lanes 10 and 11: negative controls.  Lanes 2-9 and 
13-20 as described above. 
 
3.3.5 Touchdown PCR of cervical carcinoma samples 
Application of optimised touchdown PCR reaction conditions to all samples yielded positive 
150 bp amplicons in 22/23 cases (case 56 did not amplify).  The band intensities of the 
amplicons vary in line with differential HPV burden.  Cases 19-23 (Figure 3.5 lanes 7-9) 
showed the greatest amount of amplicon while cases 39, 42, 51-56, 57 (Figure 3.5 lanes 20, 21, 
23-25, 27) showed fainter bands.  The faintest band was obtained from case 33 (Figure 3.5 lane 
12).  Negative controls showed no amplification and therefore no cross contamination (Figure 
3.5 lanes 13 and 14).  All positive sample bands were deemed to show adequate amounts of 
HPV DNA for hrHPV RT-PCR analysis.  Though case 56 did not show a positive amplicon in 
this experiment (Figure 3.5, lane 26), it was included in the RT-PCR experiments. 
  1          2        3        4           5          6        7        8          9         10       11 
300 bp 
200 bp 
100 bp 150 bp 
gDNA template (ng) 
Primer concentration (M) 
MgCl2 concentration (mM) 
Lane 
500      500      500       500      250      250      250      250 
0.5       0.5       1.0        1.0       0.5       0.5       1.0       1.0   
1.5       4.0       1.5        4.0       1.5       4.0        1.5      4.0    
  12       13       14       15        16        17       18       19       20 
300 bp 
200 bp 
100 bp 150 bp 
gDNA template (ng) 
Primer concentration (M) 
MgCl2 concentration (mM) 
Lane 
100      100     100      100       50       50         50         50  
0.5       0.5      1.0       1.0       0.5       0.5        1.0        1.0 
1.5       4.0      1.5       4.0       1.5       4.0        1.5        4.0 
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Figure 3. 5 DNA electrophoresis of all cases amplified by touchdown end-point PCR using 
GP5+/GP6+ HPV L1 primers.  Positive PCR amplicon = 150 bp (right arrow).  Standard conditions: 
100 ng genomic DNA, 0.5 µM primers, 4 mM MgCl2.  Lanes 1, 15 and 28: 100 bp molecular weight 
marker ladder, lanes 13 and 14; negative controls.  Case numbers as described above. 
 
3.4 hrHPV genotypes detected by multiplex RT-PCR on LightCycler™ 480 II 
Raw fluorescence data from the RT-PCR run was exported into Microsoft Excel.  Background 
fluorescence was subtracted from the traces to yield net fluorescence.  Graphs were plotted 
showing  cycle number versus fluorescence for all samples in all detection channels.  The cycle 
number refers to the fluorescence detected in the extension phase of PCR of a particular cycle.  
The threshold cycle (Ct), as previously described in Chapter 1.5.2.2.2, refers to the PCR cycle 
number at which the PCR amplicon fluorescence crosses the background/threshold 
fluorescence and begins exponential phase of fluorescence (Figure 1.9).  The Ct value is 
calculated by the LightCyclerTM software. 
After the runs were complete, the positive controls were first analysed to ensure that all dye 
labelled probes worked correctly.  Thereafter, negative controls and case samples were 
analysed and corresponding graphs plotted. 
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3.4.1 RT-PCR curves of supplied positive control DNA samples for hrHPV and 
human internal control, -globin 
RT-PCR of all of the positive controls was successful.  All showed exponential phase 
fluorescence below cycle 30 and therefore individual Ct values are not displayed (Figures 3.6-
3.8).  Dyes in the FAM and Cy5 spectrum were individually resolved however an issue arose 
with the JOE/ROX dyes and the available detection filter.  The Red 610 filter (533-610 nm) 
cannot distinguish the emission spectra of ROX and JOE dyes.  Therefore, HPV types in the 
JOE probe set (types 31, 35, 45 and 52) cannot be distinguished from those in the ROX probe 
set (18, 59, 66 and 68) (Figure 3.7).  It was therefore decided to establish exact hrHPV genotype 
in any sample that showed positivity in the Red 610 spectrum by DNA sequencing. 
 
Figure 3. 6 RT-PCR curves of supplied positive controls for HPV 16, 33, 39 and 58.  The 
genotype-specific hydrolysis probes were detected with FAM filter (498-550 nm). 
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Figure 3. 7 RT-PCR curves of supplied positive controls for HPV 18, 31, 45, 59, 35, 68, 52 and 
66.  Due to overlapping spectra of JOE and ROX probes, the curves are grouped as 18/31, 45/59, 35/68 
and 52/66.  The genotype-specific hydrolysis probes were detected with Red 610 filter (533-610 nm). 
 
 
Figure 3. 8 RT-PCR curves of supplied positive controls for HPV 51, 56 and -globin.  The 
genotype-specific hydrolysis probes were detected with Cy5 filter (618-660 nm). 
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3.4.2 Detection of FFPE internal control (housekeeping) genes by RT-PCR 
The Sacace kit provided two Cy5 labelled hydrolysis probes for the detection of internal control 
genes (housekeeping genes).  Only detection of one of the probes is required for the specimen 
to be considered positive.  A positive internal control with Ct>33 for hrHPV indicates that HPV 
concentration is low in the sample but that the sample DNA integrity is adequate.  A negative 
internal control with negative hrHPV (i.e. no amplification signal at all for hrHPV) would 
imply that the specimen DNA integrity was not optimal.  A negative internal control but 
positive hrHPV may occur and indicate that the DNA integrity of the target sequence(s) of the 
hrHPV genes may be better preserved than that of the internal control.  Figure 3.9 shows the 
calculated Ct for internal control of all samples. Three cases (8, 26 and 39) showed no signal 
for internal controls however good amplicon detection was achieved with touchdown endpoint 
PCR (see Figure 3.5). 
  
 44 
 
 
 
Figure 3. 9 RT-PCR curves of -globin housekeeping gene.  Cases 3 (Ct=34), 4 (Ct=33), 12 
(Ct=35), 15 (Ct=33), 19 (Ct=29), 20 (Ct=26), 23 (Ct=32), 30 (Ct=29), 33 (Ct=28) , 34 (Ct=25),  35 
(Ct=30), 37 (Ct=29), 38 (Ct=30), 42 (Ct=32), 44 (Ct=28), 51 (Ct=25), 54 (Ct=30), 55 (Ct=30), 56 (Ct=32) 
and 57 (Ct=31).  Genotype-specific hydrolysis probe was detected with Cy5 filter (618-660 nm).  Cases 
8, 26 and 39 do not show amplification. 
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3.4.3 Detection of hrHPV genotypes by multiplex RT-PCR 
Threshold cycles were calculated by the software program with the highest assigned threshold 
number being 35.  The last 5 cycles have higher uncertainty and this is termed a “late call”. 
 
Twenty two out of twenty three cases showed the presence of hrHPV with case 54 representing 
the only case with no detection of hrHPV.  The total number of hrHPV-positive cases is 
therefore 22.  Case 54 showed a positive internal control signal (Ct=30) and demonstrated weak 
but positive GP5+/GP6+ amplicon with touchdown endpoint PCR (see Figure 3.5).  Only the 
cases showing positive amplification curves for specific hrHPV genotypes are presented below 
(Figures 3.10-3.14).  A summary of the cases and their hrHPV profiles is shown in Table 3.1 
 
HPV 16  
The most common hrHPV genotype was 16, which was identified in 21/22 hrHPV cases (95%). 
Cases with relatively late threshold cycles (Ct>33) (cases 12, 33, 37, 38 and 56) showed internal 
control (-globin) curves with Ct<33 except for case 12 (Ct=35) (Figure 3.10).  These cases 
are interpreted as representing low copy numbers of HPV 16. 
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Figure 3. 10 RT-PCR curves of HPV 16.  Cases 3 (Ct=15), 4 (Ct=21), 8 (Ct=25), 12 (Ct=35), 15 
(Ct=29), 19 (Ct=25), 20 (Ct=17), 23 (Ct=16), 26 (Ct=18), 30 (Ct=25), 33 (Ct=35), 35 (Ct=20), 37 (Ct=35), 
38 (Ct=35), 39 (Ct=28), 42 (Ct=29), 44 (Ct=16), 51 (Ct=21), 55 (Ct=33), 56 (Ct=35) and 57 (Ct=21).  
Case 34 does not contain HPV 16.  Genotype-specific hydrolysis probe was detected with FAM filter 
(498-550 nm). 
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HPV 18 
 
HPV 18 was identified in 2/22 hrHPV cases (9%).  In both cases, co-infection with HPV 16 
was present. 
 
Figure 3. 11 RT-PCR curves of HPV 18.  Cases 42 (Ct=33) and 55 (Ct=27).  Genotype-specific 
hydrolysis probe detected with Red 610 filter (533-610 nm).  
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HPV 33 
HPV 33 was identified in 1/22 (4.5%) hrHPV cases with HPV 16 co-infection (case 37).  
 
Figure 3. 12 RT-PCR curve of HPV 33.  Case 37 (Ct=18).  Genotype-specific hydrolysis probe 
detected with FAM filter (498-550 nm).  
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HPV 39 and 45  
HPV 39 was identified in 2/22 cases (9%) with HPV 45 co-infection in one (case 34) and 
HPV 45 and 16 in the other (case 33).  
 
 
Figure 3. 13 RT-PCR curves of HPV 39.  Cases 33 (Ct=27) and 34 (Ct=25).  Genotype-specific 
hydrolysis probe detected with FAM filter (498-550 nm).  
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Figure 3. 14 RT-PCR curves of HPV 45.  Cases 33 (Ct=27) and 34 (Ct=25).  Genotype-specific 
hydrolysis probe detected with Red 610 filter (533-610 nm).  
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Table 3. 1 hrHPV genotypes identified by RT-PCR 
 
Case HPV 
16 
HPV 
18 
HPV 
31 
HPV 
33 
HPV 
35 
HPV 
39 
HPV 
45 
HPV 
51 
HPV 
52 
HPV 
56 
HPV 
58 
HPV 
59 
HPV 
66 
HPV 
68 
3  X X X X X X X X X X  X X 
4  X X X X X X X X X X X X X 
8  X X X X X X X X X X X X X 
12  X X X X X X X X X X X X X 
15  X X X X X X X X X X X X X 
19  X X X X X X X X X X X X X 
20  X X X X X X X X X X X X X 
23  X X X X X X X X X X X X X 
26  X X X X X X X X X X X X X 
30  X X X X X X X X X X X X X 
33  X X X X   X X X X X X X 
34 X X X X X   X X X X X X X 
35  X X X X X X X X X X X X X 
37  X X  X X X X X X X X X X 
38  X X X X X X X X X X X X X 
39  X X X X X X X X X X X X X 
42   X X X X X X X X X X X X 
44  X X X X X X X X X X X X X 
51  X X X X X X X X X X X X X 
55   X X X X X X X X X X X X 
56  X X X X X X X X X X X X X 
57  X X X X X X X X X X X X X 
Green box indicates presence of hrHPV genotype and red marks absence 
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Overall, 17 cases showed infection with a single hrHPV genotype, four cases with 2 genotypes  
and one with three (Figure 3.16). 
 
Figure 3. 15 Frequency distribution of hrHPV genotypes identified by RT-PCR 
 
 
Figure 3. 16 Number of hrHPV genotypes per case identified by RT-PCR 
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3.5 Confirmation of hrHPV L1 sequences via DNA Sanger sequencing and BLAST 
alignment 
As no specific positive control was used in the PCR experiments, DNA sequencing was chosen 
to prove that the amplicons generated by GP5+/GP6+ primers were truly HPV L1 in origin.  
Cases 20 and 23 were randomly chosen for sequencing for this purpose and sequenced using 
the GP5+ forward primer.  BLAST analysis of the obtained sequences show 100% match for 
L1 gene of HPV 16 (Table 3.2). 
 
The genotype specific primers used for cases 33, 34 and 55 show 100% matches for genotypes 
45 (cases 33 and 34) and 18 (case 55).  Case 42 did not show a match for HPV 18 or 31 (Table 
3.2).  The lack of sequencing trace in case 42 may reflect the low copy number of these 
genotypes (HPV 18/31) that may be below the threshold of the sequencing platform but within 
detection range of the RT-PCR kit.  The individual Sanger sequence traces, FASTA format 
DNA sequence and BLAST alignments are displayed in Appendix 3. 
 
Table 3. 2 BLAST alignment of DNA sequences from selected cases 
Case number Percent identity E-value* Aligned target sequence with accession number 
20 100% 9E-24 HPV 16 L1 gene (LC456606.1) 
23 100% 8E-36 HPV 16 L1 gene (LC456606.1) 
33 100% 1E-15 HPV 45 L1 gene (KU049757.1) 
34 100% 1E-23 HPV 45 L1 gene (KU049757.1) 
55 100% 2E-08 HPV 18 L1 gene (MH028425.1) 
*The E-value is the probability of obtaining the sequence alignment by chance. 
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CHAPTER FOUR 
DISCUSSION 
 
4.1 Case demographics 
The initial sample size of 57 was reduced to 23.  Exclusion of cases with sub minimal tumour 
burden reduced the initial cohort numbers by more than 50% however this was  necessary in 
order to increase the probability of extracting sufficient high quality hrHPV DNA.  At the onset 
of the study, the available literature regarding HPV DNA extraction from archival tissue 
suggested that the yield would be poor and that alternative methods for enrichment of HPV 
DNA would be necessary.  As a result, we initially focused on cases with high tumour burden 
in order to maximise the amount of HPV DNA extracted for hrHPV genotypic analysis. 
 
Cervical squamous cell carcinoma is usually diagnosed by biopsy or loop excision following 
abnormal/HSIL Pap and owing to late presentation, patients are at a clinical stage that precludes 
total abdominal hysterectomy  and will only receive chemotherapy and radiotherapy.  As such, 
tumour samples may consist of small biopsies or loop excisions where the malignant, invasive 
tumoural cells may form a small portion of the total area of the specimen.  As this study also 
excluded areas of HSIL, the numbers were further reduced.  By proving that housekeeping 
genes and hrHPV DNA were successfully amplified from archival tissue, future investigations 
will include the remainder of the outstanding cases and thereby reach the total number of 57.  
Thereafter, it is envisioned that the hrHPV genotyping RT-PCR will be applied to all cases for 
squamous cell carcinoma in that time period. 
 
Cervical squamous cell carcinoma was lowest in extremes of ages as represented by 20-29 and 
70-79 with the highest burden present in 40-49 followed by 30-39, 50-59, 60-69 (Figure 3.1). 
This age peak is similar to the mean age of 50.7 years described by van Aardt et al. (2015) in 
299 cases of cervical squamous cell carcinoma in women living in the Gauteng province of 
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South Africa.  Interestingly, the median age for HIV-negative women in that  cohort was 55.8 
years and HIV-positive women 41.4 years (p<0.0001).  Previous studies investigating cervical 
dysplasia in HIV-positive and negative women in Cape Town showed that the age groups with 
highest prevalence of HSIL (CIN II and III) are 25-29 and 30-34 years (McDonald et al., 2014) 
which may account for the bulk of invasive disease occurring in a slightly older population in 
this study. 
 
The percentage of confirmed HIV-positive patients in this pilot study was less than estimated 
in the general population (~30% amongst pregnant women, Mbulawa et al., 2015) and that 
previously published in investigations of cervical dysplasia and carcinoma in South African 
populations (Table 4.1).  More HIV-positive cases may be present in the “HIV unknown” group 
however this cannot be confirmed.   
 
Table 4. 1 HIV prevalence in South African women with CIN and cervical carcinoma  
Publication HIV-positive HIV-negative HIV unknown 
Van Aardt et al, 2015 25.8% 51.5% 22.7% 
Denny et al., 2014 24.6% 64.5% 11% 
McDonald et al., 2014 14.6% 85.4% - 
 
4.2 DNA extraction and housekeeping gene endpoint PCR 
As previously mentioned, initial review of the available literature regarding DNA extraction 
from FFPE implied potential limiting factors in achieving adequate yield of high quality DNA 
for downstream molecular analysis (Steinau et al., 2011, Cannavo et al., 2012, Zhong et al., 
2013, Heikal et al., 2014,).  The gDNA extracted from the pilot study, however, showed 
adequate concentrations and purity (see Appendix 1).  This eliminated the need for further 
investigations into alternative extraction methodologies.  The simple modification in this study 
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of overnight proteinase K digestion at 37ºC (versus 56ºC for 1 hour) yielded adequate results 
and was a more convenient workflow. 
 
Housekeeping gene endpoint PCR was successful in initial experiments of cases 3 (year 2004), 
19 (year 2008) and 56 (year 2014) using GAPDH gene primers (Figure 3.2).  PCR product 
yield was highest in 2014 and lowest in 2004, in keeping with the widely held understanding 
that increased age of FFPE specimens resulted in DNA deterioration and less efficient 
amplification.  This reduction in PCR product yield can theoretically be remedied by increasing 
gDNA template concentrations (assuming no PCR inhibitors are present) however subsequent 
reamplification PCR studies and the touchdown protocol showed no obvious difference in the 
ability of HPV L1 sequences to be successfully amplified over the entire time period studied 
(see Figures 3.5-3.8).  The housekeeping genes chosen for this study amplify products of 222bp 
and 159bp which are longer than the PCR product of HPV L1 target sequence (150 bp) with 
GP6+/GP6+ primers.  Successful amplification of housekeeping target sequences of these 
longer lengths suggested that amplification of the GP5+/GP6+ 150 bp product would be 
possible.  Therefore, alternative shorter L1 targets (e.g., via MY09/11 and SPF10 primers) were 
not investigated further.  In addition, a recent review discussing HPV detection from FFPE 
recommended the use of GP5+/GP6+ primers (Kocjan et al., 2016). Ultimately, the 
amplification of the housekeeping genes are only to prove that DNA of sufficiently good 
quality was extracted so that HPV genotyping could proceed. 
 
4.3 HPV L1 amplification by endpoint PCR 
Targeting the L1 gene by PCR is a useful screening tool as it identifies all HPV genotypes.  
Optimisation of HPV L1 endpoint PCR was necessary to show that there was adequate amounts 
of HPV DNA in the samples to proceed with RT-PCR analysis owing to the high cost of 
commercial HPV genotyping kits (R280 per sample as per 2018 pricing for the Sacace kit). 
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Initial L1 amplification experiments using GP5+/GP6+ primers were unsuccessful following 
standard published PCR conditions.  Attempts to modify the standard PCR conditions by 
adjusting various parameters (cycle numbers, annealing temperatures and times) were also 
unsuccessful (results not shown).  A reamplification PCR experiment was also performed to 
assess whether lack of PCR product was due to low HPV target sequences within extracted 
gDNA.  A PCR product of correct size was observed (Figure 3.3) but reamplification PCR was 
not  a viable option for this project as it required twice the amount of reagents (Taq polymerase, 
buffer, primers) and two PCR experiments to identify HPV.  This was considered both 
expensive in terms of biochemical consumables and time.  Also, there would be an increased 
potential for cross contamination. 
 
Investigation into alternative methods for L1 detection via GP5+/GP6+ PCR revealed a 
comprehensive paper outlining a touchdown PCR technique that increased the detection limit 
of L1 sequences by sequentially lowering the annealing temperature by 0.5C/cycle in order to 
improve the yield of amplicons and increasing the total number of cycles to 50 (Evans et al., 
2005).  The GP5+/GP6+ primers have an unusually low annealing temperature and may 
therefore not anneal under standard temperatures used in PCR reactions.  Touchdown protocol 
3 (TDP3) was chosen from the paper (Evans et al., 2005, see Table 2.5) as it showed optimal 
amplification down to a template DNA amount of 1 ng.  
 
4.4 Optimisation of touchdown PCR parameters for GP5+/GP6+ primers 
A pilot experiment for touchdown PCR was performed on case 3 as this was the oldest and 
theoretically ought to have the least amount of intact, amplifiable HPV L1 DNA.  If 
amplification was successful in this case, it was reasoned that later cases would be successfully 
amplified.  In addition to applying the published touchdown PCR conditions, further 
optimisation of gDNA concentration, primer concentration and MgCl2 concentration were 
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undertaken to maximise yield.  Mg2+ is required for annealing of template DNA and primer 
and to increase efficiency of PCR amplification.  Excessive Mg2+ can however decrease 
specificity leading to non-specific band smearing on DNA gels.  Too little, however, may result 
in no PCR amplification.  Decreasing gDNA also dilutes potential PCR inhibitors that may be 
present in the sample and also conserves gDNA for further experiments.  An initial concern 
that the increased numbers of cycles in the touchdown protocol may result in depletion of 
adequate subminimum dNTP concentrations and Taq polymerase activity were not justified.  
Touchdown PCR was successful in case 3 (Figure 3.4) and the optimised PCR conditions were 
applied to the remainder of the cases. 
 
Touchdown PCR using this method allowed for detection of HPV L1 sequences in 22/23 cases 
(Figure 3.5).  PCR product yield was not reduced in older cases compared to newer cases with 
GP5+/GP6+ touchdown PCR, unlike the trend noted in the GAPDH experiment (Figure 3.2).  
Touchdown PCR was useful in screening samples to ensure sufficient concentration of HPV 
DNA and of adequate integrity for subsequent genotype PCR amplification was present. 
 
In case 56 that did not show L1 amplification (Figure 3.5 lane 26), detection of housekeeping 
genes was successful (Figure 3.2).  This lack of amplification may therefore reflect a lower 
concentration of HPV DNA in this sample (compared to host housekeeping gene), beyond the 
threshold detection limit of DNA agarose electrophoresis rather than other factors, viz., poor 
DNA quality, PCR inhibitors.  Also possible is that the area for primer binding may have been 
fragmented and not available for annealing. 
 
4.5 Real time PCR (RT-PCR) detection of hrHPV genotypes  
The preliminary screening of samples for DNA integrity (housekeeping gene PCR) and HPV 
burden/dose (GP5+/GP6+ PCR) are necessary prior to RT-PCR due to cost concerns as 
mentioned above.  The advantage of multiplex RT-PCR however is the potential identification 
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of up to 14 hrHPV genotypes (plus internal housekeeping gene control) per sample in 4 reaction 
tubes versus 14 separate reactions.  RT-PCR also allowed for rapid determination of the 
presence/absence of target sequences in comparison to endpoint PCR that required an entire 
PCR run, gel electrophoresis, UV transillumination and digital image capture.  The case that 
showed housekeeping gene amplification but not L1 amplification (case 56) was included in 
the RT-PCR experiments as the different amplification modality, coupled with different target 
HPV DNA sequences (E6/E7 versus L1) was expected to yield positive results. 
 
One of the major limitations of the RT-PCR experiments involved the number of available 
fluorescence detection filters.  The Sacace kit required four filter set to distinguish the four 
separate dye-tagged hydrolysis probes (FAM, JOE, ROX, Cy5).  The available LightCycler™ 
480 II only had three filter set combinations.  The Red 610 filter spectra overlapped with the 
JOE and ROX dyes on the kit hydrolysis probes.  In this kit, hrHPV genotypes fall in these 
spectra (HPV 18, 31, 35, 45, 52, 59, 66 and 68) therefore only positive samples in the Red 610 
channel were confirmed by DNA sequencing and sequence alignment. 
 
Though the positive DNA samples (included with the kit) are at equal gene equivalents, there 
is a wide range of RT-PCR amplification curves and ultimately Ct values (Figures 3.8-3.10).  
This reflected differences in hydrolysis probe length and annealing chemistry at a single 
annealing temperature.  All positive controls however showed Ct<33. 
 
Detection of β-globin internal control DNA sequences was achieved in 20/23 samples with 
cases 8, 26 and 39 not being amplified (Figure 3.9).  These cases however showed 
housekeeping gene and L1 amplification in the endpoint PCR experiments (Fig 3.7) and 
subsequent RT-PCR with genotype specific hydrolysis probes (Fig 3.12).  A possible reason 
for the discrepancy may be the fragmentation of the -globin DNA  compared to either GAPDH 
or -actin.  Of note, the internal control (β-globin) had a relatively late Ct of 25 and implies 
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that this target may potentially show false negative results if total gDNA was present in lower 
concentrations.  Repeat experiments with increased gDNA concentrations may have potentially 
increased the detection of -globin (not done in current study). 
 
Overall, 22/23 (96%) of cases showed the presence of hrHPV.  Case 54 did not show RT-PCR 
amplification despite exhibiting amplification with β-globin housekeeping gene RT-PCR 
(Figure 3.9) and GP5+/GP6+ primers (Figure 3.5).  This may be due to the possible presence 
of an hrHPV gene not covered in the Sacace kit, similar to the findings by Meiring et al., 2012 
where next generation sequencing identified hrHPV genotypes present that were not covered 
in the commercial kit. 
 
HPV 16 was the most common genotype, accounting for 21/22 hrHPV cases (Figure 3.10).  As 
all cases were standardised with regards to gDNA template concentration, comparison of Ct 
values for the various cases was possible.  As such, cases 3, 23 and 44 showed the lowest Ct 
values (15, 16 and 16, respectively) indicating the highest concentrations of HPV 16 while 
cases 12, 33 and 38 showed the lowest with all having late calls at Ct=35 (Figure 3.10).  The 
most common single hrHPV infection was also HPV 16 in previous studies (Odida et al., 2008; 
Denny et al., 2014; McDonald et al., 2014; van Aardt et al., 2015) and global trends (Schiffman 
et al., 2007). 
 
HPV 18 was detected in 2/22 hrHPV cases (cases 42 and 55) with Ct values of 33 and 27, 
respectively (Figure 3.11).  HPV 18 probes are labelled with ROX dye and cannot be 
distinguished from HPV 31 (JOE dye) via the LightCyclerTM system.  These cases were Sanger 
sequencing and subsequent BLAST analysis  confirmed the genotype.  Case 55 showed a 100% 
match for HPV 18 (Table 3.2).  Case 42 however did not yield a sequence that matched to HPV 
18 despite repeating the sequencing.  The BLAST algorithm showed 100% match for HPV 16 
which is a co-infecting genotype in this case.  The lack of obtaining HPV 18 sequence in this 
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case is likely due to suboptimal target DNA concentration for Sanger sequencing, which may 
also be implied by noting that the RT-PCR curve Ct value for this case was fairly late at 33 
(Figure 3.11). 
 
HPV 33 was identified in only one case (case 37) (Figure 3.12).  This is unusual as HPV 33 is 
regarded as one of the most common hrHPV genotypes in various studies in African 
populations (see Table 4.3).  However, HPV prevalence varies from country to country and 
regions within countries and reflects difference in sexual behaviour and co- morbidities such 
as HIV infection and may account for this difference. 
 
HPV 39 was identified in cases 33 and 34 (Figure 3.13).  Identification of HPV 39 in these two 
cases is unusual as this genotype is rare in South African population (approximately 0.6%) 
while in Nigerian populations, it is 1.4% which is equivalent to HPV 33 (compared to 6.6% in 
South African populations) (Denny et al., 2014). 
 
HPV 45 was identified in cases 33 and 34 as well (Figure 3.14).  As this genotype probe was 
tagged with JOE probe and showed possible overlap with HPV 59, these cases were also Sanger 
sequenced with subsequent BLAST analysis.  These additional investigations confirmed 100% 
match with HPV 45 (Table 3.2). 
 
The relative frequency of hrHPV in this study is therefore HPV 16>>18=39=45>33. 
 
The absence of HPV 35 is unusual as it is ranked third in prevalence in Ghanian, Nigerian and 
South Africans (Denny et al., 2014),  Although tempting, care should be exercised when 
comparing the results of this limited pilot study to published results until the entire cohort has 
been analysed.  
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Table 4. 2 Most common hrHPV genotypes in cervical carcinoma in sub-Saharan Africa 
Study Population location 
and period 
hrHPV in descending 
order of prevalence 
Method of hrHPV 
identification 
Van Aardt et al., 2015 South Africa 
(2003-2004, 2008-
2011) 
16>18>35>45>33 
(HIV neg) 
16>18>45>33>58 
(HIV-positive) 
LiPA with 
GP5+/GP6+ primers 
Denny et al., 2014 Ghana, Nigeria, South 
Africa 
(2007-2010) 
16>18>35>45>33 
(South Africa) 
LiPA with SPF10 
primers  
Odida et al., 2008 Uganda 
1968-1992 
16>18>45>31>35>39 LiPA with SPF10 
primers  
Ogembo et al., 2015 23 African countries 
 
16>18>45>35>33 Various. Study was 
meta-analysis and 
systematic review 
 
4.6 HIV status and hrHPV distributions 
Out of the original cohort of 7 HIV-positive cases, only 2 HIV-positive cases contained 
sufficient tumour burden to be included in the final cohort.  Both of these cases, numbers 39 
and 56, showed infection by a single hrHPV genotype (HPV 16).  The cases with 2 hrHPV 
genotypes (cases 34, 42 and 55) were all from HIV negative patients.  The only case with 3 
hrHPV genotypes (case 33) was also from an HIV negative patient.  None of the HIV unknown 
cases showed more than one hrHPV genotype.  A large proportion of cases did not have 
documented HIV test results either in the clinical history of the pathology specimen report or 
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on the DISA system.  Nonetheless, the pilot study shows that multiple hrHPV genotypes are 
present in HIV negative cases. 
 
HIV positive status would be expected to be higher in the local community and this may have 
been demonstrated if all cases had been tested.  Van Aardt et al (2014) also showed that HIV-
positive women had more multiple hrHPV than HIV negative women (27% versus 8%, 
p=0.001).  Therefore, it is likely that future investigations into the remainder of the original 
cohort will include more HIV-positive women and may also reflect this trend.  
 
4.7 Limitations of the current study 
Limitations of the pilot study include low numbers of cases.  Large proportion of cases were 
excluded on basis of low tumour burden.  These could however be included in future with 
manual or laser microdissection techniques to preferentially extract small foci or tumour from 
surrounding involved stroma, thereby reducing the risk of diluting the HPV DNA with excess 
stromal tissue DNA.  
 
An additional limitation pertained to the available detection filters in the LightCyclerTM system. 
An alternative option would be to access another RT-PCR machine equipped with 4 filter 
detection capability (examples include Rotor-Gene™, ABI®7500), use of another dye that is 
standard with LightCycler™ 480 II in a non-overlapping spectrum (e.g., Cyan 500, 440/480 
nm) or use of alternative commercially available kits using only 3 dyes (e.g., AmoyDx® HPV 
genotyping detection kit).  With increased numbers of cases investigated, the numbers of 
detected genotypes in the JOE/ROX overlapping spectrum would increase and it would not be 
feasible to send all these for confirmation by sequencing. 
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4.8 Application to other HPV related carcinomas in different anatomical sites 
The touch down GP5+/GP6+ PCR described here together with multiplex RT-PCR can be 
applied to other FFPE archival specimens of HPV-related ano-genital and head and neck 
carcinomas.  As HPV associated carcinomas show better prognosis than HPV-negative in these 
anatomic sites, detection of hrHPV is essential.  At present, guidelines recommend the use of 
p16 as a surrogate marker for hrHPV infection but future investigations may require definitive 
proof of hrHPV DNA and/or hrHPV subtyping to direct treatment and predict prognosis.  
Indeed, it may be of interest to compare the clinical progression and treatment response of 
hrHPV positive tumours based on their particular genotype and assess if multiple hrHPV 
genotypes adversely affect prognosis compared to single genotype infections.  
 
The current study shows that the hrHPV genotype distribution overall mirrors that found in 
sub-Saharan and industrialised countries and vaccination of our local population with the 
commercially available HPV genotypes would be protective against cervical carcinoma.  
Investigation of hrHPV anogenital and oropharyngeal sites would also be of benefit to predict 
suitability for prevention of these cancers, the rates of which are increasing.  
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CHAPTER FIVE 
CONCLUSION 
 
This pilot study aimed to extract high quality DNA from FFPE cervical carcinoma cases with 
the aim to identify the hrHPV genotypes associated with each case. 
 
Conventional kit based DNA extract methods were successful in obtaining DNA of adequate 
concentration and purity.  GAPDH housekeeping gene and HPV L1 consensus sequences were 
successfully amplified by conventional and touchdown PCR techniques, respectively. 
 
The multiplex RT-PCR kit from Sacace allowed for rapid detection of multiple hrHPV 
genotypes in the samples submitted with 22 showing the presence of hrHPV.  Limitations of 
hrHPV detection in genotypes showing overlapping emission spectra in the RT-PCR setup 
were overcome by Sanger sequencing. 
 
We conclude that adequate amounts of DNA can be extracted from archival FFPE tissue using 
standard techniques and that hrHPV DNA is present in adequate amounts for RT-PCR 
amplification and genotype identification.  The positive results obtained in this study are 
encouraging and the remainder of the cohort of low tumour burden cases will be analysed in 
future experiments.  
 
Touchdown end point PCR and RT-PCR are quick and efficient methods for the simultaneous 
detection of multiple hrHPV genotypes in FFPE case samples and are well suited to upscaling 
and potential application to other HPV associated carcinoma specimens. 
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APPENDIX 1 
 
Buffers and reagents 
1. EDTA (ethylenediaminetetraacetic acid) stock solution (0.5 M).  93.06 g EDTA 
(Sigma, St. Louis, MO, USA) was dissolved in 490 ml dH2O, titrated to pH 8.0 and 
made up to a final volume of 500 ml. This solution was autoclaved and kept at room 
temperature (RT). 
2. 5X Tris-borate-EDTA (TBE) buffer stock solution:  54 g Tris, 27.5 g boric acid and 20 
ml of 0.5 M EDTA stock solution were dissolved in 980 ml of dH2O and made up to a 
final volume of 1000 ml without pH titration.  This solution was autoclaved and kept 
at RT . One part 5X TBE stock solution was diluted with 4 parts water to yield a 1X 
TBE working solution. 
3. HotStarTaq® Master Mix Kit (2X) was from QIAGEN (Valencia, CA, USA).  This 
solution, when diluted 1:1, contains final concentrations of 2.5 units HotStarTaq® 
polymerase, 1.5 mM MgCl2 and 200 M of each dNTP.  The solution was stored at -
20ºC until use.  When required, it was fully thawed, gently mixed and kept on ice.  This 
product requires an initial activation step of 15 min at 95C before the PCR cycling is 
commenced. 
4. Sterile water (Adcock Ingram, Johannesburg, South Africa).  This was aliquoted into 
1.5 ml Eppendorf tubes and kept at -20C until required. 
5. 25 mM MgCl2 stock solution (QIAGEN, Valencia, CA, USA).  This stock solution was 
diluted according to desired final concentration with the understanding that a baseline 
of 1.5 mM MgCl2 was present in the HotStarTaq
® Master Mix.  The stock solution was 
kept at -20C until required. 
6. 1.5% agarose gel:  Agarose (Bioline, London, UK) .  1.3 g of agarose was added to 80 
ml 1XTBE in a 250 ml Erlenmeyer flask, microwaved until boiling and the agarose 
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completely dissolved. The solution was cooled, stock ethidium bromide solution added 
(5 l) and poured into a Perspex mould and allowed to set at RT.  12 well gel combs 
were used.  A 1.5% agarose concentration was chosen for optimal separation of target 
DNA amplicon sizes. 
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APPENDIX 2 
 
Extracted FFPE DNA concentrations of cases 
 
Case number DNA concentration 
(ng/l) 
A260/A280 
3 309.5 1.88 
4 791.4 1.88 
8 606.4 1.81 
12 776.6 1.80 
15 685.5 1.67 
19 473.7 1.90 
20 360.1 1.87 
23 494.8 1.91 
26 774.8 1.78 
30 641.7 1.88 
33 521.0 1.94 
34 425.6 1.91 
35 387.8 1.92 
37 342.5 1.87 
38 527.2 1.92 
39 309.5 1.85 
42 136.3 1.88 
44 496.3 1.89 
51 359.5 1.67 
54 420.2 1.93 
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55 335.7 1.93 
56 91.3 1.90 
57 385.8 1.90 
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APPENDIX 3 
 
 
 
 
Case 20 
Sanger sequencing  electropherogram: 
 
 
Cleaned DNA sequence in FASTA format (5'-3'): 
ATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGT
TTATT 
 
BLAST alignment: 
Human papillomavirus type 16 K1753 DNA, complete genome 
Sequence ID: LC456606.1Length: 7905Number of Matches: 1 
Range 1: 6699 to 6762GenBankGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1  
Score Expect Identities Gaps Strand 
119 bits(64) 9e-24 64/64(100%) 0/64(0%) Plus/Plus 
Query  1     ATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGTT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  6699  ATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGTT  6758 
 
Query  61    TATT  64 
             |||| 
Sbjct  6759  TATT  6762 
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Case 23  
Sanger sequencing fluorescence trace: 
 
 
Cleaned DNA sequence in FASTA format (5'-3'): 
TATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGG
AGGAATATGATTTACAGTTTATTTTT 
 
BLAST alignment: 
Human papillomavirus type 16 K1753 DNA, complete genome 
Sequence ID: LC456606.1Length: 7905Number of Matches: 1 
Range 1: 6680 to 6765GenBankGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1  
Score Expect Identities Gaps Strand 
159 bits(86) 8e-36 86/86(100%) 0/86(0%) Plus/Plus 
Query  1     TATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  6680  TATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGG  6739 
 
Query  61    AGGAATATGATTTACAGTTTATTTTT  86 
             |||||||||||||||||||||||||| 
Sbjct  6740  AGGAATATGATTTACAGTTTATTTTT  6765 
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Case 33 
Sanger sequencing fluorescence trace: 
 
 
Cleaned DNA sequence in FASTA format (5'-3'): 
AGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTTTTCA 
 
Human papillomavirus type 45 isolate 14Uk35 minor capsid protein L2 (L2) and major capsid 
protein L1 (L1) genes, complete cds 
Sequence ID: KU049757.1Length: 2905Number of Matches: 1 
Range 1: 2466 to 2514GenBankGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1  
Score Expect Identities Gaps Strand 
91.6 bits(49) 1e-15 49/49(100%) 0/49(0%) Plus/Plus 
Query  1     AGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTTTTCA  49 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2466  AGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTTTTCA  2514 
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Case 34 
Sanger sequencing fluorescence trace: 
 
 
Cleaned DNA sequence in FASTA format (5'-3'): 
ATCCTACTAAGTTTAAGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTT
TTCA 
 
BLAST alignment: 
Human papillomavirus type 45 isolate 14Uk35 minor capsid protein L2 (L2) and major capsid protein 
L1 (L1) genes, complete cds 
Sequence ID: KU049757.1Length: 2905Number of Matches: 1 
Range 1: 2451 to 2514GenBankGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1 
Score Expect Identities Gaps Strand 
119 bits(64) 1e-23 64/64(100%) 0/64(0%) Plus/Plus 
Query  4     ATCCTACTAAGTTTAAGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTT  63 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2451  ATCCTACTAAGTTTAAGCACTATAGTAGACATGTGGAGGAATATGATTTACAGTTTATTT  2510 
 
Query  64    TTCA  67 
             |||| 
Sbjct  2511  TTCA  2514 
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Case 55 
Sanger sequencing fluorescence trace: 
 
 
Cleaned DNA sequence in FASTA format (5'-3'): 
AAGCAGTATAGCAGACATGTTGAAGAATATGATTT 
Human papillomavirus type 18 isolate 294_08 L1 gene, partial cds 
Sequence ID: MH028425.1Length: 1323Number of Matches: 1 
Range 1: 1015 to 1049GenBankGraphicsNext MatchPrevious Match 
Alignment statistics fo r match #1  
Score Expect Identities Gaps Strand 
65.8 bits(35) 2e-08 35/35(100%) 0/35(0%) Plus/Plus 
Query  1     AAGCAGTATAGCAGACATGTTGAAGAATATGATTT  35 
             ||||||||||||||||||||||||||||||||||| 
Sbjct  1015  AAGCAGTATAGCAGACATGTTGAAGAATATGATTT  1049 
 
